Quest Diagnostics introduces four new tests panels for CAH

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women. The panels are designed to overcome limitations in conventional testing to provide faster, high quality diagnosis of CAH in a single analysis.

"CAH is challenging to diagnose, and often escapes fast detection and treatment," said endocrinologist Richard E. Reitz, M.D., medical director, Quest Diagnostics, and chair, Endocrine Division, Quest Diagnostics Nichols Institute. "We designed our new CAH panels to aid in assessing the different patient populations affected by CAH using the most advanced analytical-test method available. We believe these panels will improve the quality and timeliness of diagnosis of CAH for many patients."

CAH is an endocrine disorder, typically inherited, that causes an overproduction of androgens, a family of so-called male hormones that include testosterone. The condition can accelerate the development of male features in newborns and children of both genders. In newborns, CAH can be fatal if untreated, and CAH screening of newborns shortly after birth is widely performed in the United States.

The new offerings feature a comprehensive panel for newborn screening for CAH. The panel enables analysis of all 13 steroids associated with CAH using the highly sensitive and specific liquid-chromatography tandem mass spectrometry (LC/MS/MS) measurement technique.

In addition, the test can be performed on a sample volume of 0.1 milliliter, making it well suited to newborn heel-prick sample collection.

By comparison, conventional clinical CAH test offerings generally require clinicians to measure CAH-associated steroids using different tests and require a much larger sample volume. In addition, some clinical tests are based on immunoassays, which may be less reliable at measuring levels of certain steroids in children and women than LC/MS/MS. The Endocrine Society recommends testing by LC/MS/MS to evaluate CAH and other hyper-androgenic disorders.

The company also has introduced three additional CAH panels by LC/MS/MS. One panel aids in diagnosing acute stress conditions in newborns that can be misdiagnosed for CAH. Another panel aids in diagnosing and managing children and adults with the most common forms of CAH, which are caused by 21-hydroxylase or 11-hydroxylase enzyme deficiency. A fourth panel aids in differentiating non-classic CAH from polycystic ovary syndrome (PCOS), a highly common androgen disorder in women that shares similar symptoms with CAH.

SOURCE Quest Diagnostics      

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2012, May 19). Quest Diagnostics introduces four new tests panels for CAH. News-Medical. Retrieved on November 24, 2020 from https://www.news-medical.net/news/20120519/Quest-Diagnostics-introduces-four-new-tests-panels-for-CAH.aspx.

  • MLA

    Quest Diagnostics. "Quest Diagnostics introduces four new tests panels for CAH". News-Medical. 24 November 2020. <https://www.news-medical.net/news/20120519/Quest-Diagnostics-introduces-four-new-tests-panels-for-CAH.aspx>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics introduces four new tests panels for CAH". News-Medical. https://www.news-medical.net/news/20120519/Quest-Diagnostics-introduces-four-new-tests-panels-for-CAH.aspx. (accessed November 24, 2020).

  • Harvard

    Quest Diagnostics. 2012. Quest Diagnostics introduces four new tests panels for CAH. News-Medical, viewed 24 November 2020, https://www.news-medical.net/news/20120519/Quest-Diagnostics-introduces-four-new-tests-panels-for-CAH.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
IBM, Quest Diagnostics launch new genomic tumor sequencing service to help advance precision medicine